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Phototherapy is a standard treatment for neonatal jaundice. Its relative freedom from complications together with its non-invasive nature, ease of usage, and convenience 
has resulted in widespread acceptance in virtually all neonatal 
units [1]. The increase in the amount of body water loss through 
insensible transepidermal loss due to phototherapy along with 
stool water loss is commonly seen in newborn suffering from 
jaundice [2]. Some infants with high bilirubin level are mildly 
dehydrated and may need supplemental fluid to correct their 
dehydration. Furthermore, the photoproducts responsible for 
the decline in serum bilirubin are excreted in urine and bile. 
Hence, maintaining adequate hydration and good urine output 
help to improve the efficacy of phototherapy [3]. Studies done 
on fluid supplementation on term neonates have shown variable 
results [2,4,5]. Hence, this randomized control trial was conducted 
to evaluate whether parenteral fluid supplementation helps in 
reducing the duration of phototherapy in healthy term neonates 
with non-hemolytic hyperbilirubinemia.
MATERIALS AND METHODS
This study was conducted in a tertiary level neonatal care unit of a 
teaching institute in North Karnataka over a period of 12 months 
from December 2012 to November 2013. Healthy term neonates 
(≥37 weeks) weighing ≥2.5 kg at birth presenting with jaundice 
and  total serum bilirubin (TSB) ≥15 mg/dL (256 µmol/L) from 
2nd to 14th day of life were included. Written informed consent 
was obtained from either parent of the neonate. Ethical clearance 
was obtained from the institutional ethical committee.
Neonates with bilirubin encephalopathy (hypertonia, arching, 
retrocollis,  opisthotonos,  fever,  and  high-pitched  cry)  [6], TSB 
>25  mg/dL  (428  µmol/L),  conjugated  bilirubin  >20%  of  the 
TSB, evidence of hemolysis, signs of dehydration (weight loss 
>10%  of  birth weight,  reduced  skin  turgor,  dry mucosa,  fever, 
and tachycardia), jaundice persisting beyond 14 days of life, sick 
neonates, major congenital anomalies, born to gestational diabetic 
mother, cephalhematoma, and neonates on intravenous fluid for 
any reason were excluded (Box I). Hemolysis was diagnosed if 
direct Coombs test was positive, peripheral blood smear showed 
features of hemolysis and increased reticulocyte count [7].
During the study period, 92 term neonates were admitted for 
jaundice, 28 neonates were excluded, and 4 parents refused to 
give consent (Fig.  1). Hence,  60  neonates were  randomized  to 
one  of  the  two groups  (case  group n=30,  control  group n=30). 
Neonates of both the groups received exclusive breastfeeding.
Neonates were allotted using computer-generated random 
number, and the corresponding serial numbered was opened by an 
opaque, identical envelope containing group allocation to either of the 
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two groups. Group I (case group) received supplemental intravenous 
fluid along with phototherapy and breastfeeding. Group II (control 
group) received only phototherapy and breastfeeding.
Phototherapy was provided by special blue light phototherapy 
unit  (Phoenix Blue CFL-tubes  PL-L-18W/52/4P Chennai, Tamil 
Nadu). Neonates were fully exposed except for their eyes and nappy 
areas. Phototherapy unit was placed at a distance of 25 cm over the 
neonate. Phototherapy was discontinued after TSB value obtained 
below 15 mg/dL (256 µmol/L) by 2 mg/dL (34.1 µmol/L). Neonates 
in case group received 1/3rd the daily maintenance fluid (80 mL/kg 
on day 2, 100 mL/kg on day 3, 120 mL/kg on day 4, 140 mL/kg on 
day 5, and 160 mL/kg on or after day 6) of 1/5th normal saline with 
5%  dextrose  by  peripheral  vein  till  they  received  phototherapy. 
All the neonates received exclusive breastfeeding on demand. 
Investigations  were  sent  for  serum  bilirubin  (total  and  direct), 
hemoglobin, and for evidence of hemolysis (reticulocyte count, 
direct Coombs test, and peripheral smear for hemolysis). Maternal 
blood group was obtained from mother’s records.
Neonates were periodically monitored for hydration, 
adequacy of feeding, signs of acute bilirubin encephalopathy, 
urine, and stool frequency. Daily weight was recorded. Serum 
bilirubin  (total  and  direct)  was  repeated  at  4th and 12th h and 
every 12 hourly by EM360  fully automated autoanalyzer using 
diazo method. Primary outcome measures were the duration of 
phototherapy and percentage of fall of TSB.
RESULTS
There was no significant difference with respect to birth weight, 
gender, weight at admission, mode of delivery, and age at 
admission between the two groups (Table  1).  Mean  (standard 
deviation  [SD])  percentage  of  weight  loss  (case  vs.  control 
group  was  5.09%  [2.78]  vs.  4.84%  [2.2])  was  not  significant. 
Laboratory parameters (hemoglobin, reticulocyte count, and TSB 
at  inclusion) were  similar  in both  the groups  (Table  1). Hence, 
factors affecting bilirubin was similar in both the groups.
There was a significant difference in the duration of 
phototherapy (case group 39 [7.8] h vs. control group 45.2 [10.22] h, 
p=0.0248). The average duration of phototherapy was shorter by 
6  h  in  the  fluid  supplemented  group. The  percentage  of  fall  in 
bilirubin  at  4,  12,  48,  and  60  h was  not  significant,  but  it was 
significant at 24 and 36 h (Table 2).
All the babies in both the groups responded to phototherapy, 
none of them needed exchange transfusion or developed signs 
of bilirubin encephalopathy. None of the neonates developed 
complications related to phototherapy and intravenous cannula 
(thrombophlebitis or evidence of sepsis).
DISCUSSION
Our study showed that intravenous fluid supplementation 
significantly reduced the duration of phototherapy in healthy term 
exclusively breastfed neonates presenting with non-hemolytic 
hyperbilirubinemia though the percentage of fall in bilirubin was 
not significant at all times.
The quantity of fluid supplemented differs between different 
studies. In one of the study, Iranpour R supplemented their 
study  participants  with  25%  of  the  maintenance  showed  no 
benefit [2], while a study by Mehta et al. showed benefit with 
supplementation  of  50%  of  daily maintenance  [4].  Hence,  our 
study was conducted to evaluate whether fluid supplementation 
of 1/3rd the maintenance has any benefit. We chose to give fluid 
by intravenous route as we believe that oral supplementation 
might interfere with breastfeeding, and the effectiveness of oral 
rehydration may not be sufficiently reliable and fast [4].
In a study done by Mehta et al. [4], benefit of fluid 
supplementation in term neonates presenting with severe 
Box I: Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Healthy term neonates (≥37 weeks)
≥2.5 kg at birth
Presenting with jaundice from 2nd to 14th day of life
Total serum bilirubin (TSB) ≥15 mg/dL (256 µmol/L)
Signs of bilirubin encephalopathy (hypertonia, arching, retrocollis, 
opisthotonos, fever, and high-pitched cry)[6]
TSB>25 mg/dL (428 µmol/L)
Conjugated bilirubin>20% of the TSB
Evidence of hemolysis
Signs of dehydration (weight loss>10% of birth weight, reduced skin 
turgor, dry mucosa, fever, and tachycardia)
Jaundice persisting beyond 14 days of life
Sick neonates
Major congenital anomalies
Born to gestational diabetic mother
Cephalhematoma
Neonates on intravenous fluid for any other reason
Figure 1: Patients flow diagram
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hyperbilirubinemia in the form of decreased rate of exchange 
transfusion and duration of phototherapy was seen. However, the 
case group in this study received intravenous fluid for first 8 h 
followed by oral supplementation with expressed breast milk or 
formula feeds. This study also showed the non-reliability of infants 
with own autoregulatory mechanisms to increase oral intake 
in the presence of severe hyperbilirubinemia. In a study, Saedi 
et al. [8] showed that additional parenteral fluid therapy in term 
neonates with non-hemolytic hyperbilirubinemia accelerates the 
reduction in serum bilirubin in first 24 h of admission. However, 
case group received full maintenance intravenous fluid along with 
breastfeeding. Boo and Lee [5] in a randomized controlled trial 
on severely jaundiced healthy term infants receiving intensive 
phototherapy showed no benefit of oral or intravenous fluid 
supplementation. However, the quantity of fluid given to both the 
groups (enteral and intravenous group) was similar, only the route 
of administration was different (oral vs. intravenous) and was only 
studied for first 4 h of phototherapy. A study by Goyal et al. [9] 
found no significant difference in the duration of phototherapy 
or exchange transfusion between the non-supplemented and fluid 
supplemented  (by  both  intravenous  and  oral  route)  neonates 
receiving phototherapy for severe hyperbilirubinemia.
Table 1: Demographic and laboratory parameters of the neonates*#
Parameter Case group
n=30
Control group
n=30
Male n (%) 19 (63) 16 (53)
Birth weight in kg 3.02 (0.32) 3.07 (0.34)
Admission weight (kg) 2.87 (0.31) 2.92 (0.33)
Weight loss (%) 5.09 (2.78) 4.84 (2.2)
Mode of delivery n (%)
Vaginal 11 (36.6) 11 (36.6)
Cesarean 14 (46.6) 17 (56.6)
Instrumental 5 (16.6) 2 (6.6)
Age at admission (days) 5.17 (2.07) 5.07 (1.78)
Hemoglobin (g/dL) 15.83 (1.4) 15.61 (1.39)
Reticulocyte count (%) 1.61 (0.39) 1.43 (0.76)
TSB (mg/dL) at inclusion 17.35 (1.45) 16.11 (0.04)
*Results expressed as mean (SD), #all P>0.05 between both groups. SD: Standard 
deviation, TSB: Total serum bilirubin
None of the neonates of either of the groups developed 
features of bilirubin encephalopathy or needed an exchange 
transfusion. Cochrane review showed no benefit of intravenous 
fluid supplementation on complications related to excessive 
bilirubin (bilirubin encephalopathy, kernicterus, or cerebral 
palsy)  in  healthy  term  neonates  as  a  risk  of  developing  these 
complications was very low [10]. The American Academy 
of Pediatrics [3] states that there is no evidence of excessive 
fluid administration affecting the serum bilirubin concentration 
and does not recommend routine intravenous fluid, or other 
supplementation of the term and near-term infants receive 
phototherapy unless there is evidence of dehydration. However, 
mild dehydration may not have significant clinical signs [11]. 
The significance of our finding might be due to an expansion of 
intravascular volume leading to a slight dilutional lowering of the 
bilirubin, but the more important effect would be enhanced biliary 
and bowel function [4]. Cochrane review of the previous studies 
showed that additional fluid supplementation in healthy term 
neonates with unconjugated hyperbilirubinemia shortened the 
average duration of phototherapy by 10.7 h; however, its clinical 
significance was unclear [9].
The major limitation of our study was the lack of laboratory 
parameters to determine dehydration. However, neonates of both 
the groups had no clinical signs of dehydration, weight loss on 
admission was not significant, and the possibility of subclinical 
dehydration will be equally distributed between both the groups. 
Furthermore, complete blinding was not possible in our study. 
We  could  not  rule  out  the  glucose-6-phosphate  dehydrogenase 
deficiency in our subjects due to non-availability of the 
investigation at our institution.
CONCLUSION
Parenteral fluid supplementation along with exclusive 
breastfeeding does not affect the final outcomes but helps to 
reduce the duration of phototherapy which will reduce the 
duration of hospital stay and facilitate early discharge in such 
neonates. Further studies comparing fluid supplementation by 
oral or intravenous routes with no additional fluids involving a 
large sample size are required to find the beneficial effect if any.
Table 2: Percentage of fall in TSB and duration of phototherapy
Time (h) Case group Control group p value
n % of fall in TSB n % of fall in TSB
4 30 1.42 (0.75) 30 1.22 (1.42) 0.506
12 30 6 (3.26) 30 4.63 (5.84) 0.266
24 30 11.06 (5.16) 30 6.85 (6.28) 0.006*
36 29 17.32 (6.86) 29 11.36 (7.54) 0.002*
48 8 23.89 (9.11) 16 19.02 (9.55) 0.06*
60 2 26.47 (8.14) 8 21.87 (9.44) 0.30
Total duration of phototherapy (h) 39.6 (7.8) 45.2 (10.22) 0.0248*
Results expressed as mean (SD). *Significant P<0.05. TSB: Total serum bilirubin, SD: Standard deviation
% of fall in TSB
TSB at inclusion - at specified time
TSB
=
( )
 at inclusion
×100
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